Apex Labs*

APEX Ticker Reserved**

* Apex Labs Ltd. conducts business as Apex Labs.
** Apex Labs Ltd. has reserved the ticker symbol “APEX” with the NEO Exchange. The company currently holds the NEO Exchange private company ticker symbol of “APEXL”.

Winter
2021

Why APEX?

1

Unique Value Proposition

- Collaboration with First Nations and Veterans on clinical trials and drug development
- Subsection 56(1) exemptions filed with Health Canada through TheraPsil
- Asset light model through Joint Venture (JV) agreement with Innovate to source controlled substances, accelerate supply chain and access Natural Product Numbers (NPNs)

2

Under Valued

- Current value allows for growth upon proposed listing in Q1 2022 and undervalued compared to peers
- Large private shareholder base

APEX is a socially focused pharmaceutical company.

APEX's clinical development program is focused on Veterans and First Nations - groups that are disproportionately affected by mental disorders. The Company's lead clinical candidate is a low-dose synthetic psilocin product for the treatment of Post Traumatic Stress Disorder (PTSD).

APEX's strategy is to develop drug products including Active Pharmaceutical Ingredients (API) produced by chemical synthesis, and also drug products with botanically-sourced API, differentiating **APEX** from the pack by diversifying **APEX's** options for development and commercialization of drug products.

Mission

To bring psychedelic drugs to market through commercialization of drug products and, where possible, through medical access, in both Canada and the USA.

Vision

Global Good Manufacturing Practices (GMP) supply chain secured by Joint Venture with a Licensed Dealer to create synthetic APIs, cultivate fruiting bodies and preparing botanical extracts.

Strategy

APEX aims to be at the forefront of both psilocin drug development and medical access by working directly with Veterans and First Nations. **APEX** is aligned with TheraPsil, a non-profit advocacy group focused on psilocybin medical access and assisted psychotherapy.

Directors & Officers

Tyler Powell

Chief Executive Officer & Director

Capital markets entrepreneur with 15 years of experience in the financial sector leading numerous IPO's & RTO's on North American & German Exchanges

Arron Victory

Chief Strategy Officer & Director

Ambassador for Wounded Warriors Canada & Advisor to the Chronic Pain Centre of Excellence & Heroic Hearts Project with patient & operational expertise

Dr. Orion Lekos

Chief Science Officer & Director

Led global clinical trials while being instrumental in the development & design of the extractions and formulations for a top three global cannabis company

Dr. Peter Tomlinson

Chief Medical Officer

Prominent industry leader specializing in clinical trials & pharmaceutical commercialization partnering with leading companies such as Tilray, Aegera, Purgenesis, Ultragenyx, Sharp & Taro

Sam Isaac

Chief Financial Officer

Brings 15 years of international capital markets experience, having worked with publicly traded companies and raised over $100 million in equity capital

Alex Winstead

Chief Cultivation Officer

Renowned mycologist, cultivator & founder/ CEO of Cascadia Mushrooms with over 16 years' experience in the gourmet & medicinal mushroom industry

Tom McGaugh

Director

Provides nearly two decades of financial accounting excellence & experience supporting start-ups, small businesses & publicly traded companies across the globe

Jim Pakulis

Director

Vast executive corporate experience as CEO & Director of numerous successful public & private companies across North America raising millions in conjunction

Scientific & Strategic Advisors

Scientific	
Raashid Naik	Pharmacist and Senior Director at Shopper's Drug Mart
Dr. Paul Smith	Patient Recruitment
Dr. Emmanouil Rampakakis	Clinical Trial Protocols Specialist
Dr. Jacek Usakiewicz	Drug Design and Assay Development
Dr. Lukman Sarker	Genetics and Sequencing
Dana Nohynek	Clinical Development and Regulatory Affairs
Katrina Blommaert	Psychedelic Clinical Trials Consultant
Strategic	
Dr. David Wood	Intellectual Property and Regulatory attorney
Bob Cross	Capital Markets and Innovate Joint Venture
Susan Chapelle	Operations
Darwin Douglas	First Nations Champion
Denis Silva	Corporate Securities Attorney
Martin Cronin	Veteran Advocate

Review Commitee

Veteran
Andrew Brear
Denis LeBlanc
Julianna Mercer
David Fascinato

First Nations
Justin George
Otis Jasper
Rueben George
Anthony Aure

Canadian Landscape

Mental Health Synopsis

$51B

Estimated annual economic burden of mental illness in Canada

20%

Number of Canadians who suffer from addiction in any given year

50%

Number of Canadians who will be affected by mental health issues by the age of 40

4th

Canada's worldwide rank per capita in anti-depressant drug usage

PTSD

9th

Leading cause of deaths nationwide attributed to suicide with an average of 11 per day

76%

Of Canadians have reported experiencing a traumatic event reshaping their mental health

9%

Of PTSD patients not receptive to current traditional treatments

8%

Of Canadians suffer from PTSD at least once in their lifespan

* See Footnotes on page 17

Drug Development - 3 Phase Approach

1 Research & Development

Dr. Lekos oversees Research and Development (R&D) alongside Dr. Usakiewicz and Dr. Sarker with the Innovate team to head research on genetics, extraction and formulation of botanical psilocybin products for clinical trials. Dr. Lekos will head further R&D projects using controlled substances to be added as A/QPIC* to Innovate's Dealer's Licence.

* A qualified person in charge ("QPIC") is responsible for supervising all activities with controlled substances at a licensed dealer's site. A licensed dealer may only deal with controlled substances at their site if the QPIC or an alternative QPIC ("A/QPIC") is present at the site.

2 Clinical Trial Planning

Dr. Tomlinson, Dr. Wood and Dana Nohynek will oversee regulatory efforts and manage the Clinical Trial Application (CTA) and Investigational New Drug Application (IND) for all clinical trials with help from the Clinical Research Organization (CRO) JSS Medical Research will support the clinical trials as a private CRO by auditing target sites and assisting with patient recruitment.

3 Clinical Trial Execution

Dr. Rampakakis and Dr. Tomlinson combined clinical and GMP expertise will allow **APEX** to develop, protect and commercialize drug products manufactured with GMP standards. At least two different drug products are planned for clinical trials - one with psilocin as an API and another with a botanical extract of psilocybin, other tryptamines and beta carbolines are also being evaluated.

Critical Path

1 CTA & FDA Approval

APEX is currently engaged with Health Canada and one of the world's leading patient advisory groups to launch clinical trials for Veterans, First Responders and First Nations. Having a study approved by Health Canada will simplify having a study approved by the FDA*.

2 Product Sourcing

APEX has a Joint Venture Agreement with Innovate to cultivate, extract, formulate, import and export controlled substances for the benefit of Apex's clinical trials. Innovate's DL site is built to Compliance with Level 6 of the Security Directive**, allowing ample storage of controlled substances to secure North American supply.

3 Launch

APEX will launch multiple clinical trials with Veterans, First Responders and First Nations in Canada and the US with the team that assisted the PTSD Phase 2 and Phase 3 MDMA*** clinical trials for MAPS.

** Food and Drug Administration
*** Directive on Physical Security Requirements for Controlled Substances and Drugs Containing Cannabis
*** Methylenedioxymethamphetamine

Clinical Timeline



Apex Labs

* Clinical Trial Application

Innovate Phytoceuticals - Joint Venture

Innovate and **APEX** are currently under agreement aligning both companies with access to a GMP controlled substance supply chain. **APEX** is assisting with their expertise in GMP certification, extraction methods, genetics and mycology along with funding to bolster Innovate's already expansive team and network. In return, **APEX** has a royalty program in place securing early revenue streams mutually benefitting both outfits.

About Innovate:

Innovate Phytoceuticals is a cutting edge 10,000 square foot Biosafety Level 2 Laboratory providing standard & non-standard analytical testing, R&D, formulation, regulatory and genetic services as well as API and technology development.

The Innovate team includes experts in regulatory, molecular science, epigenetics, plant science, chemistry, formulation science, microbiology and tissue culture. Employing the latest technology, Innovate's Health Canada licences includes, Controlled Substances Dealer's Licence, Pathogen & Toxicology, Cannabis Analytical and Cannabis Research – Institution Wide, Cannabis Nursery and Natural Health Product Site Licence.



Patient Recruitment

APEX is working with JSS Research to further identify how Veterans, First Responders and First Nations can benefit from psychedelic-supported psychotherapy based on clinical evidence.



Veterans

APEX's Veteran-focused research team will be studying PTSD, traumatic brain injury and chronic pain in the Canadian and American Veteran and First Responder communities. We believe in a whole-person approach to recovery for Veterans and First Responders who suffer from chronic service-related conditions with patient support from Dr. Paul Smith.

First Nations

APEX's collaboration with Indigenous groups is bolstered by its association with All Nations Wellness Corp. (ANW) and Indigenous leaders in Canada and the US including representatives from the Cheam First Nation, Tsleil-Waututh Nation, Upper Nicola Band, Stk'emlúpsemc te Secwépemc Nation, and Shxwhá:y Village. We are working with ANW and the other members of Indigenous team to engage with Medical Doctors and patients eligible for clinical trials.

Intellectual Property

Genetic Registration & Rights

APEX intellectual property development plan prioritizes patent protection of development genetics, compositions, formulations and target indications for drug products. We combine these aspects together to bolster and diversify our patent claims, particularly in formulations prepared from extracts of botanical biomass and synthetic forms.

There is an incredible opportunity for developing and securing intellectual property rights in the psilocybin, psilocin and psychedelic space. **APEX** is working hand-in-hand with our intellectual property counsel at Cooley LLP, DLA Piper (USA) LLP and R-Group Legal, identifying the assets that can be protected and effectively captured to capitalize on.

Revenue Model

1

5% Royalty

APEX receives 5% gross royalty on all goods and materials produced in Innovate's GMP manufacturing room including Natural Health Products.

2

20% Royalty

APEX receives 20% gross royalty on all projects, goods and services brought by **APEX** to Innovates lab and sold under GMP compliance.

3

Product Sales

APEX has the ability to sell controlled substances to other Dealer's Licences and federal DEA* licence holders for profit.

4

Approved Drug Products

Develop a psilocin drug product, a botanical extract and/or synthetics through established regulatory processes.

* Drug Enforcement Administration

Capital Structure

Basic Structure	21.9mm
Options (@ $0.25)	6.5mm
Warrants (@ $0.20)	6.5mm
Half Warrants (@ $0.50)	6.8mm
Fully Diluted	38.3mm
Price of raise	$0.50
Units (Half Warrant $0.75)	8.0mm
Basic Proforma Market Cap	$15.0mm
FD Proforma Market Cap	$23.2mm
FD Proforma Cash	$10.6mm
Current Cash Position	$2.0mm

Use of Proceeds

Clinical Program Development	$1.5mm
Joint Venture with Dealer’s License	$500k
Drug Development & Manufacturing	$500k
IPO Related Expenses	$250k
Marketing	$500k
Working Capital and Fees	$750k

* Numbers may be suject to change.

Partners & Associates

Innomar Strategies
Health Canada liaison and literature research

Changemark Research
Site Operations & Regulatory

Cooley LLC
Top US Patent Firm

All Nations Wellness
First Nations owned & operated Indigenous Wellness Company

AlthoTech
GMP certification expert consulting outfit

DLA Piper (Canada) LLP
Leading global legal firm managing the corporate, securities and go public path for **APEX**

R-Group Law
Law firm handling **APEX's** Canadian Regulatory and IP

JSS Medical Research
Clinical Research Organization (CRO) handling clinical trials and protocols

Cascadia Mushrooms
Pacific Northwest leader in organic fungi cultivation

Innovate Phytotechnologies
10,000 square foot state-of-the-art lab facility with active Dealer's Licence

Footnotes

Global Stats

www.ncbi.nlm.nih.gov/pmc/articles/PMC6394282
www.who.int/news-room/fact-sheets/detail/depression
www.who.int/substance_abuse/information-sheet/en
www.who.int/whr/2001/media_centre/press_release/en

Canadian Stats

www.cpa.ca/sections/traumaticstress/simplefacts
www.health.gov.on.ca/en/public/publications/mental/depression.aspx https://www.addictioncenter.com/addiction/addiction-in-canada
www.canada.ca/en/public-health/services/publications/diseases-conditions/mood-anxiety-disorders-canada

Disclaimer

NOTICE TO INVESTORS

This presentation (the "Presentation") is being issued by Apex Labs Ltd. (the "Company") for information purposes, confidential and proprietary materials, and may contain certain material information about the Company, including important disclosures and risk factors applicable to the Company and the proposed private placement offering (the "Offering") of securities of the Company (the "Securities") the proposed as further described in this Presentation. The purpose of this Presentation is to provide information regarding the Company, including with respect to the Company's business, operations, and the psychedelics industry generally. This Presentation has not been prepared to assist any reader in making a decision whether to invest in the Company and the contents of this Presentation have not been approved or disapproved by any securities commission or regulatory authority in Canada, the United States or any other jurisdiction. In making an investment decision, prospective investors must rely on their own examination of the Company and the terms of the Offering as further detailed in the term sheet accompanying this Presentation (the "Term Sheet"), as applicable, including the merits and risks involved in purchasing the Securities. Prospective investors should not construe the contents of this presentation as legal, tax, investment or accounting advice by the Company or any of its directors, officers, shareholders, agents, employees or advisors. This Presentation does not take into account the particular investment objectives or financial circumstances of any prospective investor. Each prospective investor who reviews this Presentation must make its own independent assessment of the Company and the Securities after making such investigations and each prospective investor is strongly urged to consult with its own advisors with respect to legal, tax, regulatory, financial and accounting consequences, including the merits and risks involved, of any investment in the Company and its Securities.

By purchasing securities offered under this Presentation, each investor is deemed to acknowledge that its express wish is that all documents evidencing or relating in any way to the sale of the Securities be drafted in the English language only. En souscrivant des valeurs mobilières en vertu de la présente notice d'offre, chaque souscripteur est réputé reconnaître avoir exigé que tous les documents faisant foi de ou relatifs à la vente des valeurs mobilières soient rédigés uniquement en anglais.

This Presentation contains highly confidential information regarding the investments, strategy and organization of the Company and is being delivered to you in reliance on your agreement in the following sentences. Your acceptance of this document constitutes, and shall be deemed to constitute, your agreement to (i) keep confidential all the information contained in this Presentation, as well as any information derived by you from the information contained in this Presentation (collectively, "Confidential Information") and not disclose any such Confidential Information to any other person, (ii) not use any of the Confidential Information for any purpose other than to evaluate the purchase of Securities of the Company, (iii) not copy this document without the Company's prior consent, and (iv) promptly return this document and any copies hereof to the Company upon the Company's request.

In making an investment decision, prospective investors should rely on their own examination of the Company and the terms of the Private Placement, including the merits and risks involved. Prospective investors should not construe the contents of this Presentation as legal, tax, investment or accounting advice by the Company or any of its directors, officers, shareholders, agents, employees or advisors. This Presentation does not take into account the particular investment objectives or financial circumstances of any specific party who may receive it. Each party who reviews this Presentation must make its own independent assessment of the Company after making such investigations and each prospective investor is strongly urged to consult with its own advisors with respect to legal, tax, regulatory, financial and accounting consequences, including the merits and the risks involved, of any investment in the Company. In particular, any estimates, projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumption and each recipient should satisfy itself in relation to such matters. Investment in the Company is suitable only for sophisticated investors and requires the financial ability and willingness to accept the high risks and lack of liquidity that are characteristic of an investment in "seed" or "risk" capital for an entity which is in a speculative stage of development.

Certain information contained herein includes market and industry data that has been obtained from or is based upon estimates derived from third party sources, including industry publications, reports and websites. Third party sources may state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance or guarantee as to the accuracy or completeness of included data. Although the data is believed to be reliable, neither the Company nor its agents have independently verified the accuracy, currency, reliability or completeness of any of the information from third party sources referred to in this Presentation or ascertained from the underlying economic assumptions relied upon by such sources. The Company and its agents hereby disclaim any responsibility or liability whatsoever in respect of any third party sources of market and industry data or information.

This Presentation has not been independently verified and the information contained within may be subject to updating, revision, verification and further amendment. Except as otherwise provided for herein, neither the Company, nor its directors, officers, shareholders, agents, employees or advisors give, has given or has authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, currency, reliability or completeness of the information or opinions in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers and liability therefore is expressly disclaimed for any loss howsoever arising, directly or indirectly, from any use of such information or opinions or otherwise arising in connection therewith.

Except as may be required by applicable law, in furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies or omissions.

CONFIDENTIALITY NOTICE

Information contained in this Presentation is the property of the Company and it is made available strictly for the purposes referred to above in the "Notice to Investors" (the "Permitted Purpose"). By accepting this Presentation, each recipient agrees that it will not copy, reproduce, disclose or distribute to others this Presentation or the information contained herein, in whole or in part, at any time, without the prior written consent of the Company. The recipient further agrees that it and each of its directors, officers, employees and representatives shall use this Presentation only for the Permitted Purpose and for no other purpose. The recipient acknowledges and agrees that the information contained herein: constitutes the Company's proprietary information; is valuable proprietary and confidential information of the Company developed at considerable cost and effort; and that such information is the sole and exclusive property of the Company. The recipient further acknowledges and agrees that it shall not obtain any rights or licenses in, ownership of or entitlements to any of such proprietary information or any underlying intellectual property rights.

NOTICE REGARDING FORWARD LOOKING INFORMATION

Certain information included in this Presentation constitutes forward looking information under applicable securities legislation that involve substantial known and unknown risks and uncertainties. This information relates to future events or future performance of the Company. Forward-looking information are statements that are not historical facts and are often, but not always, identified using words or phrases such as "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "predict", "seek", "propose", "expect", "potential", "continue", and other similar expressions. In particular, but without limiting the foregoing, this Presentation contains forward-looking information pertaining to, among other things: the terms of the transactions proposed and certain other transactions described in this Presentation (the "Transactions"); expectations regarding the timing of steps to complete the Transactions; future growth plans; the capitalization and debt levels of the Company; the intention of the Company to seek out and target acquisitions; the effects of the Transactions; the Company's growth and business strategies; targeted customer base and resulting revenues in the near to mid term; the Company's ability to develop drug products from both synthetic and botanically sources compounds; the successful completion of the forthcoming clinical trials; the Company's ability to market and showcase the benefits of extracted botanically-sourced tryptamines, beta-carbonlines and other compounds, and also of single-molecule synthetic psilocin; Dr. Lekos heading further R&D projects using controlled substances to be added as A/QPIC to Innovate's dealer's license (once issued); the Company's relationship with JSS Medical Research in its support of the clinical trials as a private CRO; the two additional drug products planned for clinical trials; and the Company's relationship with JSS Research to further identify how Veterans, First Responders and First Nations can benefit from psychedelic supported psychotherapy from an evidence-based perspective.By its nature, forward-looking information involves known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated. Such forward-looking information is provided for the purpose of providing information about management's current expectations and plans relating to the future. Investors are cautioned that reliance on such information may not be appropriate for other purposes, such as making investment decisions. These factors and risks include, without limitation: risks that all necessary regulatory and third party approvals will not be forthcoming; risks that parties to the Transactions will not be satisfied with their respective due diligence procedures; risks that the parties will not be able to identify appropriate risks associated with drug development involving extracts from naturally occurring psychedelic alkaloids; exchange rate fluctuations; changes in legislation affecting psilocybin and other psychoactive based compounds and additives; uncertainties resulting from potential delays or changes in plans with respect to the acquisition and development of future facilities; risks involving the Company's dependency on its strategic partners to develop and commercialize its product; the reliance on key scientific advisors to led the research and development effort and bring the development of the Company's product to market; the reliance on key advisors with assisting the Company navigate the applicable legal and regulatory framework; and the discussions with multiple laboratories that have successfully synthesized psychedelics fails to materialized With respect to forward looking information in this Presentation, the Company has made assumptions, regarding, among other things: shareholder and regulatory approvals for the Transactions and the receipt of those approvals; assumptions regarding the success of the production of synthetic psychedilec compounds, assumptions regarding the success of extraction and isolation of natural psychedelic compounds; the expected market size of the global psychedelics industry; the availability of capital; current legislation; and general economic conditions. Although the Company believes that the expectations reflected in such forward looking information are reasonable, such statements are not guarantees of future performance and actual results may differ materially from those in statements of forward-looking information. Undue reliance should not be placed on forward looking information because the Company can give no assurance that such expectations will prove to be correct and such statements are based on the beliefs, estimates and opinions of the Company's management on the date such statements are made. Many factors could cause the Company's actual results, performance or achievements to vary from those described herein. Should one or more of these risks or uncertainties materialize, or should assumptions underlying forward looking information prove incorrect, actual results may differ materially from those described in this Presentation as intended, planned, anticipated, believed, estimated or expected.

The forward-looking information included in this Presentation is expressly qualified in its entirety by this cautionary statement. The Company cautions that the foregoing lists of assumptions, risks and uncertainties is not exhaustive. The forward-looking information contained in this Presentation is made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward looking information, whether as a result of new information, future events or otherwise, unless required by applicable securities laws.

Any financial outlook or future oriented financial information in this document, as defined by applicable securities legislation, has been approved by management of the Company. Such financial outlook or future oriented financial information is provided for the purpose of providing information about management's current expectations and management's plans relating to the future of the Company. Readers are cautioned that reliance on such information may not be appropriate for other purposes.

Market data and industry forecasts contained in this Presentation have been obtained from industry publications, various publicly available sources and subscription-based reports as well as from management's good faith estimates, which are derived from management's knowledge of the industry and independent sources that management believes to be reliable. Industry publications, publicly-available sources and subscription-based reports generally state that the information contained therein has been obtained from sources believed to be reliable. We have not independently verified any of the information from such third-party sources nor have we ascertained the validity or accuracy of the underlying economic assumptions relied upon therein. The Company hereby disclaims any responsibility or liability whatsoever in respect of any third party sources of market and industry data or information.

PURCHASER'S STATUTORY RIGHTS OF RECISSION

Securities legislation in certain of the provinces and territories of Canada provides purchasers with a statutory right of action for damages or rescission in cases where an offering memorandum or any amendment thereto contains an untrue statement of a material fact or omits to state a material fact that is required to be stated or is necessary to make any statement contained therein not misleading in light of the circumstances in which it was made (a "misrepresentation"). These rights, or notice with respect thereto, must be exercised or delivered, as the case may be, by purchasers within the time limits prescribed and are subject to the defences and limitations contained under the applicable securities legislation. The subscription agreement for any investment in the securities of the Company will include summaries of these rescission rights and prospective purchasers should refer to the securities legislation applicable in their province or territory along with the regulations, rules and policy statements thereunder for the complete text of these provisions or should consult with their legal advisor.

Thank You

Apex Labs

Chris Brown
info@apexlabs.com